Drugs / PEGylated recombinant human granulocyte colony
PEGylated recombinant human granulocyte colony
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04129710 Background | Jan 2020 → Dec 2023 | primary central nervous system lymphoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEGylated recombinant human granulocyte colony | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04129710 ↗ |
| Modality | Protein / enzyme biologic | “PEGylated recombinant human granulocyte colony 100 ug/kg subcutaneous injection on day 5.” NCT04129710 ↗ |
| Route | Subcutaneous | “PEGylated recombinant human granulocyte colony 100 ug/kg subcutaneous injection on day 5.” NCT04129710 ↗ |